Use of the CNB is foundational to treatment planning to identify patients with early-stage ER + HER-2- BC and lobular histology, low-intermediate grade tumours, or low-risk genomic assays results for whom neoadjuvant endocrine treatment can be administered when surgery is deferred. This evidence concerns the gene ERBB2 and breast cancer.